Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of TRV130 in Patients Experiencing Moderate to Severe Acute Pain

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of TRV130 in Patients Experiencing Moderate to Severe Acute Pain

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Jun 2014

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Oliceridine (Primary)
  • Indications Acute pain
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Trevena

Most Recent Events

  • 11 Jun 2014 According to the Trevena media release, first part of this trial is completed and second part of the study, which tests the effects of subjects metabolic capacity on TRV 130 potential duration of action is in progress.
  • 11 Jun 2014 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top